BMO Cuts Cardiome Pharma (CRME) to Market Perform Amid Vernakalant News
Tweet
Share
E-mailGet Alerts CRME Hot Sheet
Price: $2.33 --0%
Rating Summary:
8 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 2 | Down: 6 | New: 5
Rating Summary:
8 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 2 | Down: 6 | New: 5
Join SI Premium – FREE
An analyst at BMO Capital downgraded shares of Cardiome Pharma (NASDAQ: CRME) from Outperform to Market Perform Monday morning following news Merck (NYSE: MRK) has discontinued further development of vernakalant. Shares of Cardiome are down nearly 54 percent amid the news.
For an analyst ratings summary and ratings history on Cardiome Pharma click here. For more ratings news on Cardiome Pharma click here.
For an analyst ratings summary and ratings history on Cardiome Pharma click here. For more ratings news on Cardiome Pharma click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BMO Capital Resumes Global Net Lease (GNL), Upgrades to Outperform
- Citi Downgrades JB Hi-Fi Ltd (JBH:AU) to Neutral
- UBS Downgrades Scor SE (SCR:FP) (SCRYY) to Sell
Create E-mail Alert Related Categories
DowngradesRelated Entities
BMO CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
